Telotristat Ethyl

Introduction Overview

Generic Name

telotristat ethyl

Brand Name

Xermelo

Dosage Form

tablet (250 mg)

Drug Class

Miscellaneous gastrointestinal agents

Pharmacokinetics

Absorption: Telotristat ethyl is administered orally and has been shown to be well absorbed in the gastrointestinal tract when taken with food. Following oral administration, peak plasma concentrations of telotristat ethyl's active metabolite, telotristat etiprate, are typically reached within 1 to 2 hours. Food increases the rate and extent of absorption, thus administration with food is recommended to optimize bioavailability. The oral bioavailability of the active moiety supports consistent systemic exposure necessary for efficacy. Factors such as variability in gastrointestinal motility or co-administration with other drugs affecting gastric pH or motility can potentially influence absorption to a minor extent.

Distribution: Telotristat etiprate demonstrates moderate plasma protein binding, primarily to albumin, which influences its distribution profile. The volume of distribution is moderate, indicating that the drug distributes beyond the vascular compartment but with limited penetration into the central nervous system due to its physicochemical properties and efflux transporters at the blood-brain barrier. Animal and human pharmacokinetic data suggest that telotristat ethyl and its metabolites are distributed mainly to systemic circulation and peripheral tissues involved in serotonin biosynthesis, especially neuroendocrine tumor sites. No significant accumulation in tissues unrelated to target sites has been observed in clinical studies.

Metabolism: Telotristat ethyl is a prodrug that undergoes rapid hydrolysis by esterases to its active metabolite, telotristat etiprate (free base). The metabolism primarily occurs in the liver, with additional minor contributions from the intestinal mucosa. Telotristat etiprate is further metabolized mainly via oxidative pathways predominantly involving cytochrome P450 enzymes, although not extensively. The metabolic pathways do not produce pharmacologically active metabolites other than the primary active metabolite. Phase II conjugation pathways, including glucuronidation, are also involved in producing inactive metabolites excreted in bile and urine. The involvement of cytochrome P450 enzymes is relatively low, reducing the risk of significant drug-drug interactions.

Elimination: Telotristat etiprate and its metabolites are eliminated primarily via fecal excretion, accounting for the majority of elimination, with a smaller proportion excreted renally. The half-life of the active metabolite is approximately 5 hours, supporting a thrice-daily dosing regimen. Renal impairment has minimal effect on overall clearance, but since elimination pathways include biliary and fecal routes, hepatic impairment may influence pharmacokinetics and requires cautious use or dosing adjustment in severe cases. Clinical trials suggest no clinically meaningful accumulation with repeated dosing, demonstrating a stable pharmacokinetic profile suitable for chronic administration in patients with carcinoid syndrome diarrhea.

Dosage Forms

Available Dosage Forms: Telotristat ethyl is commercially available as oral tablets, each containing 250 mg of the active drug. These tablets are to be taken orally with food to optimize absorption.

Dosages for Adults and Adolescents: The approved and usual adult dose of telotristat ethyl is one 250 mg tablet taken three times daily with food. This regimen has been established based on extensive clinical trials, including pivotal phase III studies, to provide optimal efficacy in reducing carcinoid syndrome diarrhea symptoms. Treatment should be maintained as prescribed in combination with somatostatin analog therapy.

Specific Patient Populations: Telotristat ethyl is indicated for adult patients with carcinoid syndrome diarrhea inadequately controlled by somatostatin analogs. It is not approved for pediatric patients under 18 years of age. Although pharmacokinetic data are limited in severe hepatic or renal impairment, cautious use is advised, and no official dosage adjustments are recommended for mild to moderate impairment. Telotristat ethyl tablets come in monthly packaging containing four weekly boxes with seven daily doses each, facilitating adherence to the thrice-daily dosing schedule. Patients are advised to keep tablets in their original packaging until administration to preserve stability.

Mechanism Of Action

Telotristat ethyl operates as a selective inhibitor of tryptophan hydroxylase (TPH), the rate-limiting enzyme in serotonin biosynthesis. By specifically targeting the TPH enzyme, telotristat ethyl serves to reduce peripheral serotonin production, which is chiefly responsible for the debilitating symptoms seen in carcinoid syndrome diarrhea. This enzymatic blockade decreases the synthesis of serotonin in neuroendocrine tumor cells, thereby directly targeting the key mediator of diarrhea in carcinoid syndrome.

Upon oral administration, telotristat ethyl is rapidly converted by esterases into its active metabolite, telotristat etiprate. The active moiety crosses into peripheral tissues, especially those where serotonin is produced in excess, such as metastatic neuroendocrine tumors. By inhibiting TPH, telotristat etiprate effectively lowers systemic serotonin levels without significant central nervous system penetration, minimizing adverse neuropsychiatric effects.

At the cellular level, the inhibition of tryptophan hydroxylase results in reduced conversion of the amino acid tryptophan to 5-hydroxytryptophan, a serotonin precursor. This biochemical interruption curtails serotonin accumulation in the gut and bloodstream, reducing gastrointestinal motility and secretory processes that cause diarrhea. The clinical reduction in serotonin correlates with decreased frequency of bowel movements, substantially improving patient quality of life.

Comparatively, telotristat ethyl differs mechanistically from somatostatin analogs like octreotide, which primarily inhibit the release of serotonin from tumor cells. Combining telotristat ethyl’s inhibition of serotonin biosynthesis with somatostatin analogs’ suppression of serotonin secretion offers a synergistic approach, enhancing symptomatic control. Clinical studies demonstrate that this dual therapy significantly improves carcinoid syndrome diarrhea in patients unresponsive to somatostatin analogs alone, affirming its unique and complementary mechanism.

Pharmacological Actions

Selective peripheral inhibition of tryptophan hydroxylase enzyme reducing serotonin synthesis.
Reduction of excessive serotonin levels responsible for carcinoid syndrome diarrhea.
Improvement of gastrointestinal motility by decreasing serotonin-induced stimulation.
Synergistic action with somatostatin analogs in controlling carcinoid symptoms.
Minimal central nervous system penetration, limiting neuropsychiatric side effects.
Rapid conversion from prodrug to active metabolite enhancing bioavailability.
Normalization of urinary 5-hydroxyindoleacetic acid (5-HIAA), a serotonin metabolite marker.
Modulation of neuroendocrine tumor secretory activity without cytotoxic effects.
Oral administration route ensuring ease of chronic outpatient therapy.
Favorable pharmacokinetic profile supporting thrice-daily dosing.

Therapeutic Or Clinical Uses

Treatment of carcinoid syndrome diarrhea in adults.
Used adjunctively with somatostatin analogs for patients inadequately controlled on SSA monotherapy.
Reduction of serotonin-induced diarrhea symptoms associated with metastatic neuroendocrine tumors.
Improvement of quality of life in patients with carcinoid syndrome by reducing bowel movement frequency.
Management of refractory carcinoid diarrhea when standard therapies are insufficient.
Reduction of urinary 5-HIAA levels as a biomarker response during therapy.
Chronic outpatient therapy for symptom control in metastatic neuroendocrine tumor patients.
Therapeutic option for patients ineligible or intolerant to chemotherapy.
Adjunct to symptomatic management optimizing control of carcinoid syndrome manifestations.
Utility in combination regimens targeting multiple serotonin pathway points.

Side Or Adverse Effects

Nausea occurring in approximately 13% of treated patients.
Headache reported by roughly 11% of patients.
Depressed mood documented in about 9% of patients.
Elevation of liver enzymes such as gamma-glutamyl transferase (GGT) seen in 9%.
Gastrointestinal symptoms including gas (7%) and loss of appetite (7%).
Peripheral edema (swelling of hands or feet) in around 7% of patients.
Fever reported in approximately 7% of patients.
Serious hypersensitivity reactions including urticaria or angioedema in rare cases.
Severe constipation risk requiring monitoring and possible treatment discontinuation.
Severe or worsening abdominal pain as a warning sign during therapy.
Potential for drug-related hepatotoxicity warrants periodic liver function tests.
General tolerability is acceptable with most adverse effects mild to moderate in intensity.
Potential mood changes necessitate psychiatric monitoring in vulnerable individuals.

Precautions

Use with caution in patients with a history of liver disease; monitor liver function tests during therapy.
Not recommended for pediatric patients under 18 years due to lack of safety and efficacy data.
Monitor for signs of severe constipation or abdominal pain which may necessitate drug discontinuation.
Assess psychiatric history as depressive symptoms have been reported; provide appropriate psychological support.
Avoid abrupt discontinuation without physician guidance.
Ensure adherence to prescribed combination therapy with somatostatin analogs for optimal outcomes.
Inform healthcare providers of all concomitant medications to assess drug interaction risks.
Use caution in patients with renal impairment; although minimal renal clearance, clinical data limited.
Advise patients on importance of adherence to three times daily dosing with food.
Monitor patients closely during initiation and dose adjustments.
Educate patients to report any allergic symptoms immediately.
Pregnancy and breastfeeding safety not established; use only if clearly needed.
Maintain regular follow-up for assessment of therapeutic response and side effects.

Warnings

Not approved for pediatric use; safety and effectiveness in individuals under 18 years unknown.
Discontinue promptly if severe constipation or persistent abdominal pain occurs.
Potential for hypersensitivity reactions including anaphylaxis; patients should seek immediate medical attention if symptoms arise.
Use only as prescribed; do not alter dose or frequency without medical advice.
Monitor liver enzymes during treatment; elevations may require dose adjustment or discontinuation.
May reduce efficacy of CYP3A4 substrate drugs; caution with concomitant CYP3A4 substrates such as midazolam.
Avoid overdose; in case of suspected overdose, seek emergency medical attention immediately.
Long-term safety profile still being evaluated; monitor for emerging adverse effects.
Limited data in hepatic impairment; use with caution and under specialist supervision.
Risk of drug interactions necessitates thorough medication history review.

Contraindication

Known hypersensitivity to telotristat ethyl or any component of the formulation.
Patients with severe or uncontrolled hepatic impairment.
Pediatric patients below 18 years due to lack of safety data.
Concomitant use with drugs contraindicated with TPH inhibitors (if identified in future updates).
Patients with known severe allergy to excipients in the tablet formulation such as lactose or polyethylene glycol.
Patients with a history of severe constipation intolerant to treatment with serotonin-modifying agents.
Other contraindications as identified by formal regulatory guidance and updated labeling.

Drug Interactions

Telotristat ethyl may reduce the plasma concentrations of CYP3A4 substrate drugs due to enzyme induction or other mechanisms; for example, midazolam efficacy may decrease.
Concomitant use with somatostatin analogs is standard but requires monitoring for additive gastrointestinal adverse effects.
No significant interactions expected with CYP2D6 or CYP2C9 substrates based on existing data.
Potential interaction with drugs influencing tryptophan metabolism has not been fully elucidated; caution advised.
Co-administration with drugs causing constipation may increase risk of severe constipation.
No significant effect on warfarin observed; however, routine monitoring advised.
Other pharmacokinetic or pharmacodynamic interactions remain under investigation.
Herbal supplements and over-the-counter products should be reported to healthcare providers due to limited interaction data.
Concurrent use with drugs highly dependent on CYP3A4 metabolism may require dose adjustments.
Drug interaction checker tools and healthcare provider consultation recommended prior to initiation.
Interactions with serotonergic agents unknown; caution warranted to avoid serotonin imbalance.

Preparations Of The Drug

Telotristat ethyl 250 mg tablets (Xermelo) supplied in monthly packaging containing 4 weekly boxes.
Each weekly box contains 7 daily doses, facilitating adherence to three times daily dosing schedule.
Tablets include inactive ingredients such as colloidal silicon dioxide, croscarmellose sodium, hydroxypropyl cellulose, lactose anhydrous, macrogol/polyethylene glycol (PEG), magnesium stearate, polyvinyl alcohol (partially hydrolyzed), talc, and titanium dioxide.
Storage instructions include maintaining at controlled room temperature 25°C (77°F) with permitted excursions between 15°C to 30°C (59°F to 86°F).
Packaging designed to protect tablets until use; patients advised to keep tablets in original packaging until administration.
Formulation intended for oral administration with food to optimize absorption and minimize gastrointestinal side effects.
Manufactured by Lexicon Pharmaceuticals, Inc., with ongoing quality control to ensure consistency and purity.
Available only by prescription for adult patients under specialist supervision.
Not available as injectable or alternative formulations; oral tablet is sole marketed preparation.
Comprehensive prescribing information (package insert) provided for healthcare professionals with detailed clinical pharmacology and administration guidelines.